Sort   by:  
 Page size 
UnknownAdo-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Not available
S-EPMC6366814 | biostudies-literature
GenomicsMemorial Sloan Kettering Cancer Center - Human Oncology & Pathogenesis Program (HOOP) - Data Access Committee
Data Access Committee EGAC00001000305
EGAC00001000305 | EGA
TranscriptomicsPI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors and selective PI3Kα inhibitors are in clinical development. The activity of these agents, however, is not homogenous and only a fraction of patients bearing PIK3CA-mutant ER-posi...
ORGANISM(S): Homo sapiens 
2015-04-29 | E-GEOD-64033 | biostudies-arrayexpress
Genomicsena-DATASET-MGH-10-02-2015-15:19:45:352-2 - samples
DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. WG sequencing produced ~30-fold (primary tumour, spleen normal)-50-fold (lung metastasis) coverage
EGAD00001001253 | EGA
Genomicsena-DATASET-MGH-10-02-2015-15:17:58:985-1 - samples
DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. For WE sequencing we user Hybrid capture (Nimblegen version 3.0) of the lymph node and lung metastases, primary tumour and spleen normal; we generated ~1...
EGAD00001001252 | EGA
GenomicsTherapeutic Resistance to PI3K-alpha Inhibitors
We have studied the tumor genomic evolution in a patient with metastatic breast cancer bearing an activating PIK3CA mutation. The patient was treated with the PI3Kα inhibitor BYL719 and achieved a lasting clinical response on BYL719, but eventually progressed to treatment and died shortly thereafter...
EGAS00001000991 | EGA
TranscriptomicsAXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Phosphoinositide-3-kinase (PI3K)-α inhibitors are clinically active in squamous carcinoma (SCC) of the head and neck (H&N) bearing mutations or amplification of PIK3CA. We aimed to identify potential mechanism of resistance and have observed that SCCs cells overcome the antitumor effects of the PI3K...
ORGANISM(S): Homo sapiens 
2015-04-12 | E-GEOD-61515 | biostudies-arrayexpress
Sort   by:  
 Page size